Bannockburn, Ill.-based Baxalta Inc. is helping set the pace toward another active year for partnership and licensing transactions. Late last month the company completed its second deal, reporting it was hooking up with Precision Bioscience Inc. in a potential $1.7 billion, six-target cancer deal centered on its gene editing technology. Baxalta paid $105 million up front with the rest earmarked for milestone payments.